Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)

This study has been completed.
Information provided by (Responsible Party):
Kwang-Woo Lee, MD, Soonchunhyang University Hospital Identifier:
First received: February 2, 2012
Last updated: January 24, 2015
Last verified: January 2015
The aim of the study is to investigate if the combination therapy consisting of anticholinergics plus alpha-blockers could be beneficial for women suffering from Overactive Bladder (OAB).

Condition Intervention Phase
Overactive Bladder
Drug: Solifenacin
Drug: Solifenacin plus Tamsulosin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study

Resource links provided by NLM:

Further study details as provided by Soonchunhyang University Hospital:

Primary Outcome Measures:
  • Change in Mean Number of Micturition Episodes Per 24 Hours [ Time Frame: at week 24 relative to baseline ]

Secondary Outcome Measures:
  • Numeric Change of Urgency Episodes Per 24 Hours [ Time Frame: at week 24 relative to baseline ]
  • Change in Total Score of OABSS [ Time Frame: at week 24 relative to baseline ]
    Total Score of OABSS(Overactive Bladder Symptom Score) is the sum of 4 questions, ranging from 0 (best possible outcome) to 15 (worst possible outcome)

  • Change in Score of IPSS [ Time Frame: at week 24 relative to baseline ]
    Total Score of IPSS(International Prostate Symptom Score) is the sum of 7 questions, ranging from 0 (best possible outcome) to 35 (worst possible outcome). The 7 symptom questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 for a total of maximum 35 points.

  • Change of PVR [ Time Frame: at week 24 relative to baseline ]
    Change from baseline in Post-Void Residual (PVR) volume

  • Change of Qmax [ Time Frame: at week 24 relative to baseline ]
    maximal urinary flow rate (Qmax) assessed by uroflowmetry

Enrollment: 70
Study Start Date: December 2010
Study Completion Date: February 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Solifenacin Drug: Solifenacin
Solifenacin (5mg, qd, oral)
Other Name: Vesicare
Experimental: Solifenacin plus Tamsulosin Drug: Solifenacin plus Tamsulosin
Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
Other Names:
  • Vesicare
  • Harnal

Detailed Description:

Overactive bladder (OAB) describes the symptom complex of urgency, with or without urge incontinence, usually with frequency and nocturia.

The lower urinary tract is innervated by both the parasympathetic and the sympathetic nervous system, that act via muscarinic and adrenergic receptors, respectively.

Antimuscarinics are mainly used for the treatment of patients with OAB, especially women. Other than antimuscarinics, a1-blockers have been shown in several clinical reports to be useful in treating DO caused by neurological diseases.


Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female aged 20 ≤ and < 70 years
  • History of OAB symptoms for ≥ 3 months
  • International Prostate Symptom Score (IPSS) ≥ 8 points at Screening and more than 3 in total score and 2 in Q 3 index from OABSS questionnaire
  • An average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency (defined as a level of 3 to 5 in a 5 point Urinary Sensation Scale) episode (with or without incontinence) per 24 hours as documented in a 3-day micturition diary

Exclusion Criteria:

  • Uroflowmetry - Q max ≤ 10 mL/sec, or Post Void Residual Volume ≥ 15% of voided urine
  • Any condition that would contraindicate their usage of anticholinergics or alpha blockers
  • History of lower urinary tract surgery (e.g. incontinence surgery or electrostimulation)
  • History of stress urinary incontinence or urinary retention
  • History of interstitial cystitis, bladder outlet obstruction or other significant genitourinary disorder
  • Pregnant or nursing women
  • Current urinary tract infection
  • Neurological bladder dysfunction
  • Treatment with drugs that may interfere with CYP3A4 metabolic function
  • Significant hepatic or renal disease
  • Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01533597

Korea, Republic of
Soonchunhyang University Bucheon Hospital
Bucheon, Gyeonggi-do, Korea, Republic of, 420-767
Sponsors and Collaborators
Soonchunhyang University Hospital
Principal Investigator: Kwang Woo Lee, Ph.D Soonchunhyang University Hospital
  More Information

Responsible Party: Kwang-Woo Lee, MD, Clinical Professor, Soonchunhyang University Hospital Identifier: NCT01533597     History of Changes
Other Study ID Numbers: Bomnal study
Study First Received: February 2, 2012
Results First Received: January 11, 2015
Last Updated: January 24, 2015

Keywords provided by Soonchunhyang University Hospital:
Overactive bladder
Solifenacin succinate

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Solifenacin Succinate
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on April 28, 2017